Log In
BCIQ
Print this Print this
 

CTX-1301

  Manage Alerts
Collapse Summary General Information
Company Cingulate Therapeutics LLC
Description 
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat attention deficit hyperactivity disorder (ADHD)
Regulatory Designation
PartnerCatalent Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today